Form 8-K - Current report:
SEC Accession No. 0000320017-16-000085
Filing Date
2016-01-06
Accepted
2016-01-06 16:04:32
Documents
2
Period of Report
2016-01-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K 01.06.16 a8k010616.htm 8-K 37361
2 EXHIBIT 99.1 PR 01.06.16 exhibit991pr010616.htm EX-99.1 22813
  Complete submission text file 0000320017-16-000085.txt   61765
Mailing Address 420 LEXINGTON AVENUE SUITE 350 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 350 NEW YORK NY 10170 212-584-4171
Caladrius Biosciences, Inc. (Filer) CIK: 0000320017 (see all company filings)

EIN.: 222343568 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33650 | Film No.: 161326832
SIC: 8090 Services-Misc Health & Allied Services, NEC